31431 Tirzepatide for Sale
Compare supplier listings for Tirzepatide (CAS 2023788-19-2) — check price, grade and packaging, then open a product page or send an inquiry. View Suppliers
Premium Synthesis Biomolecule Tirzepatide CAS 2023788-19-2 Regulatory-Compliant Bio-Chemical Intermediate Subcontracting Supply Bulk Commercial Offer
-
Price:
$35/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
Desalinated Bulk Tirzepatide Peptide CAS 2023788-19-2 Ultra-Low Moisture Content Raw Powder Confirmed by Nuclear Magnetic Resonance Spectroscopy
-
Price:
$35/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
100% Reship Policy Tirzepatide Peptide CAS 2023788-19-2 Safe Stealth Packaging Door to Door Delivery
-
Price:
$30/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
Pharmaceutical Grade Tirzepatide CAS 20237Pharmaceutical Grade Tirzepatide CAS 2023788-19-2 Raw Pe88-19-2 Raw Peptide Powder with HPLC MS COA Verified
-
Price:
$30/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
Ready to Ship Tirzepatide CAS 2023788Ready to Ship Tirzepatide CAS 2023788-19-2 Spot Supply-19-2 Spot Supply Dispatched in 24 Hours Trackable Shipping
-
Price:
$30/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
Products You May Be Interested in
High Purity 99% Tirzepatide Powder CAS 2023788-19-2 Lyophilized Peptide 5mg 10mg 15mg Vials
-
Price:
$30/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
Chemical Synthesis Peptide Tirzepatide CAS 2023788-19-2 GIP GLP-1 Receptor Dual Agonist for R&D
-
Price:
$30/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
US EU Canada Warehouse Stock Tirzepatide CAS 2023788-19-2 Fast Local Shipping No Customs Issues
-
Price:
$30/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
Direct Factory Price Tirzepatide Powder CAS 2023788-19-2 Continuous Stock Quick Online Quotation
-
Price:
$30/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
Bulk Production Tirzepatide Peptide Powder CAS 2023788-19-2 Stable Supply Chain Wholesaler Price
-
Price:
$30/UNIT FOB
-
CAS No.:
2023788-19-2
-
Grade:
Pharmaceutical Grade
-
Content:
99%
-
Packaging:
10 bottles per case
- Buying Tirzepatide on www.echemi.com where you will find large variety of good choices. Suppliers of 31431 Tirzepatide registered will be verified by the accurate information. Safe transaction of chemical will be made based on true information. We help you get chemicals in need continuously and meet registered Tirzepatide suppliers.
- The quality of Tirzepatide 2023788-19-2 will be secured by ECHEMI. The pursuit of high quality requires all partners of ECHEMI to be screened, whether its certificate, qualification or scale. Tirzepatide will reach global regulation and requirement of various regions. Further services on the whole supply chain can be provided with ECHEMI.
- We offer reasonable and fair market price of Tirzepatide to provide better products and services. Services of Tirzepatide like trade data and market price and insight can be subscribed on ECHEMI. You can enjoy the chemical supply chain services on ECHEMI. We will help you purchase Tirzepatide and run fast your business.
- •China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
- •Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
- •Novo Nordisk’s Semaglutide Faces Strong Competition: Eli Lilly’s Tirzepatide Officially Launched in China
- •Eli Lilly Revenue Reaches $31.5 Billion, Up 27%! Tirzepatide and Semaglutide Exceed $20 Billion
- •Novo Nordisk's 2024 Earnings Surge by 23%! Diabetes Drug Sales Skyrocket, but Facing Competition Pressure from Tirzepatide